Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Charlottesville, Virginia 22908


This protocol will provide islet cell transplantation to two separate populations in need of a pancreas transplant: Group I: Islet Cell Transplantation in Type I Diabetics without Kidney Problems Group II: Islet Cell Transplantation in Type I Diabetics Who Have a Stable Functioning Kidney Transplant The targeted patients have very brittle diabetes or dangerous hypoglycemic unawareness and may benefit from transplantation over continuing insulin therapy, even though chronic immunosuppression is required. We believe that in these patients, the islet transplant procedure promises enough potential benefit to justify subjecting patients who have not previously had a transplant to the risk of immunosuppression. In patients who are already subject to the dangers of chronic immunosuppression for other reasons, i.e. to prevent rejection of a kidney allograft, the islet transplantation procedure itself is the principal additional risk and this risk should be minimal. In these patients (our Group II), the potential benefit from improved glycemic control is that it promises to slow or even reverse diabetic complications, such as vascular problems leading to kidney damage. It is this rationale that has made pancreas transplantation a widely accepted option in patients with renal failure, despite the risks associated with whole pancreas transplantation. Islet cell transplantation aims to provide a potentially lower risk procedure that has similar relief from diabetic complications.


Inclusion Criteria: - Type I Diabetes Mellitus for at least 5 years - Unstable control of diabetes despite intensive care by an endocrinologist, including episodes of dangerously low blood sugars - Group I must have healthy kidneys - Group II (islet after kidney) must have a stable kidney allograft for at least 6 months Exclusion Criteria: - Unstable diabetic eye disease - Poor kidney function - Type II Diabetes as determined by blood tests - Any history of cancer, except certain skin cancers - Pregnant or unwilling to use adequate birth control - Very high hemoglobin A1c levels - Poor control of blood pressure, despite use of medications - Very high insulin requirements - History of exposure to HIV - Active Hepatitis B or Hepatitis C infection



Primary Contact:

Principal Investigator
Kenneth Brayman, MD, PhD
University of Virginia

Backup Contact:


Location Contact:

Charlottesville, Virginia 22908
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.